🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,557 results for “placebo” Clear

  1. TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, Placebo to match LY, Retatrutide, Placebo to match LY

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  2. TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  3. TOCILIZUMAB, Placebo of Tocilizumab

    Pari Pharma GmbH

    Giant cell arteritis with Cerebro-vascular involvement

    phase 3 small molecule active

    1 trial

  4. TOCILIZUMAB, Tarlatamab, DEXAMETHASONE, Placebo for Tarlatamab (AMG-757), PARACETAMOL , ELECTROLYTES , PREDNISOLONE , Tarlatamab, VASOPRESSIN (ARGIPRESSIN) , SILTUXIMAB

    Amgen

    Limited-Stage Small-Cell Lung Cancer (LS SCLC)

    phase 3 small molecule active

    1 trial

  5. TQJ230, INCLISIRAN, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease (ASCVD)

    phase 3 small molecule active

    1 trial

  6. TQJ230, Placebo to TQJ230 80 mg/0.8 mL Solution for injection in pre-filled syringe with needle safety device

    Novartis Pharmaceuticals

    Apheresis

    phase 3 small molecule active

    1 trial

  7. TREPROSTINIL PALMITIL INHALATION POWDER, TREPROSTINIL PALMITIL INHALATION POWDER, Placebo (inhalation powder capsules) containing 1 of 3 dosage strengths of TPIP (80 μg, 160 μg, or 320 μg), TREPROSTINIL PALMITIL INHALATION POWDER

    Insmed Limited

    Pulmonary Arterial Hypertension

    phase 3 small molecule active

    1 trial

  8. Tablet placebo for aficamten 5mg tablet, Aficamten

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  9. Taldefgrobep, Placebo Solution for injection in pre-filled syringe, Taldefgrobep

    Lacuna Pharma Pty Ltd

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  10. Tebipenem pivoxil, SODIUM CHLORIDE, IMIPENEM AND CILASTATIN , Placebo to match Tebipenem pivoxil, tablet

    Spero Therapeutics

    complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)

    phase 3 small molecule active

    1 trial

  11. Tecentriq 1 200 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq placebo

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  12. Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab

    Hoffmann-La Roche

    Non-squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  13. Tecentriq Placebo, Abraxane 5 mg/ml powder for dispersion for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion, Gemcitabine 38 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml Intravenous Infusion, Cisplatin 1mg/ml concentrate for solution for infusion

    Hoffmann-La Roche

    Early-Stage Resectable Non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  14. Tecentriq concentrate for solution for infusion placebo 0mg, Tecentriq 840 mg concentrate for solution for infusion

    Hoffmann-La Roche

    High-risk muscle-invasive bladder cancer

    phase 3 small molecule active

    1 trial

  15. Ted sc placebo, VRDN (Insulin-like growth factor-1 receptor [IGF-1R] inhibitor with half-life extension)

    Viridian Pharma Ltd

    Thyroid eye disease

    phase 3 small molecule active

    1 trial

  16. Temodal 100 mg hard capsules, Temodal 250 mg hard capsules, Placebo, 2-Hydroxyoleic acid sodium salt, Temodal 140 mg hard capsules, Temodal 5 mg hard capsules, Temodal 20 mg hard capsules, Temodal 180 mg hard capsules

    Lacuna Pharma Pty Ltd

    Newly diagnosed primary glioblastoma multiforme (ndGBM)

    phase 3 small molecule active

    1 trial

  17. Teplizumab, Matched placebo for test product

    Sanofi-aventis Healthcare Pty Ltd

    Nutritional and metabolic diseases

    phase 3 small molecule active

    1 trial

  18. Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic obstructive pulmonary disease (COPD)

    phase 3 small molecule active

    1 trial

  19. Tezepelumab-placebo, Tezspire 210 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule active

    1 trial

  20. Tezspire 210 mg solution for injection in pre-filled syringe, Tezepelumab-placebo

    AstraZeneca AB

    Eosinophilic esophagitis (EoE) is a rare, chronic inflammatory disorder triggered by an immune response to foods and aeroantigens and characterized by a combination of esophageal dysfunction and eosinophilic infiltration of the esophagus

    phase 3 small molecule active

    1 trial

  21. The MIN-102 Placebo is supplied as an oral suspension with similar appearance to MIN-102 drug product. MIN-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose.

    Minoryx Therapeutics S.L.

    Cerebral adrenoleukodystrophy (cALD)

    phase 3 small molecule active

    1 trial

  22. The Placebo Nebuliser Solution is a solution dosage form for nebulisation identical to Treprostinil Nebuliser Solution drug product except for the absence of the treprostinil drug substance., Treprostinil

    United Therapeutics Europe Ltd

    Idiopathic Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  23. The placebo for NW-3509 drug product contains blended lactose monohydrate (29.50 mg/caps), microcrystalline cellulose (70.00 mg/caps), and magnesium stearate (0.50 mg/caps) filled into hard gelatin capsules.

    Lacuna Pharma Pty Ltd

    treatment-resistant schizophrenia (TRS)

    phase 3 small molecule active

    1 trial

  24. The placebo has the same composition as the investigational medicinal product Clinitrat® (6.563+175,4+89,3+23,3) mg/sachet (with the exception of the active substance), is manufactured by the same manufacturer (uni-pharma kleon tsetis pharmaceutical laboratory s.a) and is not sterile., CLINITRAT® (6.563+175,4+89,3+23,3) mg/sachet ή stick, Κόνις για πόσιμο διάλυμα

    Lacuna Pharma Pty Ltd

    Second line treatment for colonoscopy preparation

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources